Abstract
FGFR3 is a prognostic and predictive marker and is a validated therapeutic target in urothelial bladder cancer. Its utility as a marker and target in the context of immunotherapy is incompletely understood. We review the role of FGFR3 in bladder cancer and discuss preclinical and clinical clues of its effectiveness as a patient selection factor and therapeutic target in the era of immunotherapy.
Keywords:
bladder cancer; fibroblast growth factor receptor; immunotherapy; pharmacogenetics; targeted molecular therapy.
Copyright © 2020 Kacew and Sweis.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Animals
-
Biomarkers, Tumor / genetics*
-
Biomarkers, Tumor / metabolism
-
Clinical Decision-Making
-
Humans
-
Immune Checkpoint Inhibitors / therapeutic use
-
Immunotherapy
-
Molecular Targeted Therapy
-
Prognosis
-
Receptor, Fibroblast Growth Factor, Type 3 / antagonists & inhibitors
-
Receptor, Fibroblast Growth Factor, Type 3 / genetics*
-
Receptor, Fibroblast Growth Factor, Type 3 / metabolism
-
Urinary Bladder Neoplasms / drug therapy
-
Urinary Bladder Neoplasms / genetics*
-
Urinary Bladder Neoplasms / immunology
-
Urinary Bladder Neoplasms / metabolism
-
Urothelium / drug effects
-
Urothelium / immunology
-
Urothelium / metabolism*
-
Urothelium / pathology
Substances
-
Biomarkers, Tumor
-
Immune Checkpoint Inhibitors
-
FGFR3 protein, human
-
Receptor, Fibroblast Growth Factor, Type 3